Described herein are compositions and techniques for treatment of disease and conditions such as pulmonary arterial hypertension (PAH). Unlike palliative or preventive measures that do not address the abnormal vasculature causing onset of right ventricular compensation the use of stem cell-based therapy can directly impact the microvascular pathology in PAH, thereby reversing the course of the disease.

The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

It is intended to develop a technique that can reproduce a microenvironment of cancer tissue and to construct a novel drug discovery screening system of high precision. It is also intended to provide a method for reconstituting human cancer tissue using primary human cancer cells that retain the properties of human tumor. The present invention provides a reconstituted cancer organoid reproducing a cancer microenvironment. The present invention also provides a method for preparing a cancer organoid from cancer tissue, a xenograft prepared from the cancer organoid, a method for preparing the xenograft, a method for evaluating treatment resistance of cancer, a method for evaluating invasion or metastasis of cancer, a method for evaluating recurrence of cancer, and a method for conducting prognostic prediction of cancer.

It is intended to develop a technique that can reproduce a microenvironment of cancer tissue and to construct a novel drug discovery screening system of high precision. It is also intended to provide a method for reconstituting human cancer tissue using primary human cancer cells that retain the properties of human tumor. The present invention provides a reconstituted cancer organoid reproducing a cancer microenvironment. The present invention also provides a method for preparing a cancer organoid from cancer tissue, a xenograft prepared from the cancer organoid, a method for preparing the xenograft, a method for evaluating treatment resistance of cancer, a method for evaluating invasion or metastasis of cancer, a method for evaluating recurrence of cancer, and a method for conducting prognostic prediction of cancer.

Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response. The present invention relates generally to the treatment of human cancer and, more specifically, to use of several treatment modalities in combination to induce effective anti-tumor immune responses.

The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.

The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.

Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber; an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.

Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber; an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.